Portal de investigação
Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults.
Autores da FMUP
Participantes de fora da FMUP
- Perez-de-Llano L
- Scelo G
- Tran TN
- Le TT
- Fagerås M
- Cosio BG
- Peters M
- Pfeffer PE
- Al-Ahmad M
- Al-Lehebi RO
- Altraja A
- Bergeron C
- Bjermer LH
- Bjerrum AS
- Bulathsinhala L
- Busby J
- Cano Rosales DJ
- Canonica GW
- Carter VA
- Charriot J
- Christoff GC
- Denton EJ
- Dorscheid DR
- Fernandez Sanchez MJ
- Gibson PG
- Goh CYY
- Heaney LG
- Heffler E
- Hew M
- Iwanaga T
- Katial R
- Koh MS
- Kuna P
- Larenas-Linnemann DES
- Lehtimäki L
- Mahboub B
- Martin N
- Matsumoto H
- Menzies-Gow AN
- Papadopoulos NG
- Popov TA
- Porsbjerg CM
- Patel P
- Rhee CK
- Sadatsafavi M
- Taillé C
- Torres-Duque CA
- Tsai MJ
- Ulrik CS
- Upham JW
- von Bülow A
- Wang E
- Wechsler ME
- Price DB
Unidades de investigação
Abstract
Rationale: There is no consensus on criteria to include in an asthma remission definition in real life. Factors associated with achieving remission after biologic initiation remain poorly understood. Objectives: To quantify the proportion of adults with severe asthma achieving multidomain-defined remission after biologic initiation and identify prebiologic characteristics associated with achieving remission that may be used to predict it. Methods: This was a longitudinal cohort study using data from 23 countries from the International Severe Asthma Registry. Four asthma outcome domains were assessed in the 1 year before and after biologic initiation. A priori-defined remission cutoffs were: 0 exacerbations/yr, no long-term oral corticosteroid (LTOCS), partly/well-controlled asthma, and percent predicted FEV(1) ? 80%. Remission was defined using two (exacerbations + LTOCS), three (+control or +lung function), and four of these domains. The association between prebiologic characteristics and postbiologic remission was assessed by multivariable analysis. Measurements and Main Results: A total of 50.2%, 33.5%, 25.8%, and 20.3% of patients met criteria for two-, three- (+control), three- (+lung function), and four-domain remission, respectively. The odds of achieving four-domain remission decreased by 15% for every additional 10 years of asthma duration (odds ratio, 0.85; 95% confidence interval, 0.73-1.00). The odds of remission increased in those with fewer exacerbations per year, lower LTOCS daily dose, better control, and better lung function before biologic initiation. Conclusions: One in five patients achieved four-domain remission within 1 year of biologic initiation. Patients with less severe impairment and shorter asthma duration at initiation had a greater chance of achieving remission after biologic treatment, indicating that biologic treatment should not be delayed if remission is the goal.
Dados da publicação
- ISSN/ISSNe:
- 1073-449X, 1535-4970
- Tipo:
- Article
- Páginas:
- 869-880
American Journal of Respiratory and Critical Care Medicine American Thoracic Society
Documentos
- Não há documentos
Filiações
Keywords
- anti-IL4Ra; anti-IL5/5R; anti-IgE; exacerbation; lung function
Proyectos asociados
Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal (EPI-ASTHMA) - NCT05169619
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (EPI-ASTHMA) . AstraZeneca . 2021
Effect of a Mobile App on Improving Asthma Control in Adolescents and Adults With Persistent Asthma: A Pilot Randomized Multicentre, Superiority Clinical Trial (mINSPIRERS) - NCT05129527
Investigador Principal: João de Almeida Lopes da Fonseca
Ensaio Clínico Académico (mINSPIRERS) . 2021
Utilização em estudos observacionais do Registo de Asma Grave Portugal.
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Observacional Académico (RAG) . 2020
Clinical Research Collaboration Severe Heterogenous Asthma Research collaboration, Patient-centered (CRC SHARP).
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (SHARP) . European Respiratory Society . 2021
Multidimensional phenotyping of severe asthma patients and its impact on disease control and therapeutic response - analysis from the Portuguese Severe Asthma Registry.
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (RAG-SPP-GSK) . SPPneumologia . 2022
BREATHE - An oBservational, pRimary data study to characterize severe AsThma pHenotypes and assEss disease burden across the EUCAN region.
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (RAG-AZ-BREATHE) . AstraZeneca . 2022
Efficiency in Spine Care ? Assessing outcomes and costs to inform healthcare improvement
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2022
Use of secondary data, health technology assessment methods and economic modelling applied to penicillin allergy
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Using different data sources for the identification of asthma patients and those at high risk of adverse outcomes
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Phenotypes of Chronic Diseases of the Airways: Towards Multidimensional Data -Driven Profiling
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Citar a publicação
Perez L,Scelo G,Tran TN,Le TT,Fagerås M,Cosio BG,Peters M,Pfeffer PE,Al M,Al RO,Altraja A,Bergeron C,Bjermer LH,Bjerrum AS,Bulathsinhala L,Busby J,Cano DJ,Canonica GW,Carter VA,Charriot J,Christoff GC,Denton EJ,Dorscheid DR,Fernandez MJ,Fonseca JA,Gibson PG,Goh CYY,Heaney LG,Heffler E,Hew M,Iwanaga T,Katial R,Koh MS,Kuna P,Larenas D,Lehtimäki L,Mahboub B,Martin N,Matsumoto H,Menzies AN,Papadopoulos NG,Popov TA,Porsbjerg CM,Patel P,Rhee CK,Sadatsafavi M,Taillé C,Torres CA,Tsai MJ,Ulrik CS,Upham JW,von A,Wang E,Wechsler ME,Price DB. Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults. Am. J. Respir. Crit. Care Med. 2024. 210. (7):p. 869-880. IF:24,700. (1).
